Literature DB >> 8766570

Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production.

X Peng1, A Kasran, P A Warmerdam, M de Boer, J L Ceuppens.   

Abstract

The interaction of CD40 ligand (CD40L) on activated T cells with CD40 on B cells, monocytes and dendritic cells is essential for humoral immunity and for up-regulation of antigen-presenting cell (APC) functions, as a result of signaling through CD40. There are also some indications that after interaction with CD40, CD40L can directly signal T cells. In this study we demonstrate that upon stimulation of human peripheral blood T cells through the T cell receptor (TCR)/CD3 complex, CD40/CD40L interaction strongly enhances the production of Th1 cytokines such as interleukin (IL)-2 and interferon (IFN)-gamma and Th2 cytokines such as IL-4, IL-5 and IL-10 by a direct effect on T cells. Furthermore, CD40/CD40L interaction synergizes with IL-12 in selectively enhancing IFN-gamma production by purified anti-CD3-stimulated T cells. These effects were observed at both the protein and the mRNA level. Both CD4+ and CD8+ T cells were able to produce IFN-gamma in the presence of helper signals from IL-12 and CD40, although CD8+ T cells were less active. Since CD40/CD40L interaction also up-regulates IL-12 production and B7 expression by APC, our results suggest that CD40/CD40L interaction is bidirectional, and promotes activation of both APC and T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8766570     DOI: 10.1002/eji.1830260732

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

Review 1.  Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

2.  Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets.

Authors:  G Stuhler; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Authors:  Kevin J Curran; Beatrijs A Seinstra; Yan Nikhamin; Raymond Yeh; Yelena Usachenko; Dayenne G van Leeuwen; Terence Purdon; Hollie J Pegram; Renier J Brentjens
Journal:  Mol Ther       Date:  2015-01-13       Impact factor: 11.454

4.  CD40-CD40L cross-talk drives fascin expression in dendritic cells for efficient antigen presentation to CD4+ T cells.

Authors:  Diana M Elizondo; Temesgen E Andargie; Dineeta S Kubhar; Ayele Gugssa; Michael W Lipscomb
Journal:  Int Immunol       Date:  2017-03-01       Impact factor: 4.823

5.  Dendritic cell maturation occurs through the inhibition of GSK-3β.

Authors:  Alessandro Alessandrini; Stephanie De Haseth; Michael Fray; Masahiro Miyajima; Robert B Colvin; Winfred W Williams; A Benedict Cosimi; Gilles Benichou
Journal:  Cell Immunol       Date:  2011-04-30       Impact factor: 4.868

6.  Effects of anti-IL-4 receptor monoclonal antibody on in vitro T cell cytokine levels: IL-4 production by T cells from non-atopic donors.

Authors:  D M Bullens; A Kasran; X Peng; K Lorré; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

7.  Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation.

Authors:  Elizabeth V Clarke; Brian M Weist; Craig M Walsh; Andrea J Tenner
Journal:  J Leukoc Biol       Date:  2014-11-07       Impact factor: 4.962

8.  The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis.

Authors:  G Reichmann; W Walker; E N Villegas; L Craig; G Cai; J Alexander; C A Hunter
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

9.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

10.  Ustekinumab in the therapy of chronic plaque psoriasis.

Authors:  Jenna L O'Neill; Robert E Kalb
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.